Novo Nordisk reported 82.1M in Interest Expense on Debt for its fiscal quarter ending in September of 2024.


Interest Expense On Debt Change Date
ANI Pharmaceuticals USD 5.44M 46K Jun/2025
Aurora Cannabis CAD 1.78M 491K Jun/2025
Bausch Health Companies USD 465M 135M Jun/2025
Bristol-Myers Squibb USD 485M 9M Jun/2025
Canopy Growth CAD 9.74M 7.03M Jun/2025
Corcept Therapeutics 6M 6M Jun/2024
Drreddys Laboratories INR 817M 60M Dec/2024
Eli Lilly USD 249M 5.3M Jun/2025
GlaxoSmithKline 184M 22M Jun/2025
Merck USD 305M 8M Jun/2025
Novartis USD 289M 19M Jun/2025
Novo Nordisk 4.96B 225M Jun/2025
Pacira USD 3.82M 110K Jun/2025
Perrigo 39.6M 600K Jun/2025
Prestige Brands USD 10.2M 275K Jun/2025
Sanofi 148M 65M Jun/2025
Supernus Pharmaceuticals USD 0 0 Dec/2024
Zoetis USD 53M 1000K Jun/2025